Smallpox

Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering

Retrieved on: 
Friday, September 29, 2023
Long COVID, Prader–Willi syndrome, Sumatriptan, Failure, Telephone, Drug Master File, Autoimmunity, Pain, Acquisition, Madison Avenue, Psychiatry, Therapy, Capital market, SL, Research, Infection, Risk, Orphan drug, Security (finance), FDA, Health, COVID-19, Cancer, Smallpox, Disease, Government, Breakthrough therapy, Hydrogen chloride, MDD, Annual report, Neurology, Form, CD40L, Central nervous system, CNS, Sale, Prospectus, S-3, DSM-IV codes, Nature, Fibromyalgia, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

The closing of the public offering is expected to take place on or about October 3, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the public offering is expected to take place on or about October 3, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds of the offering will be approximately $4.5 million before deducting placement agent fees and other estimated offering expenses payable by the Company.
  • Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-placement agent for the offering.
  • The offering will be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that Tonix may file with the SEC.

Tonix Pharmaceuticals Announces Proposed Public Offering

Retrieved on: 
Thursday, September 28, 2023
Long COVID, Prader–Willi syndrome, Sumatriptan, Failure, Binge eating disorder, Telephone, Drug Master File, PPAR, Upsher-Smith Laboratories, Autoimmunity, Pain, Acquisition, Social anxiety disorder, Madison Avenue, Migraine, Psychiatry, Headache, Therapy, Capital market, SL, Research, Infection, Risk, Orphan drug, Security (finance), FDA, Long, COVID-19, Cancer, Smallpox, Disease, Government, Breakthrough therapy, Hydrogen chloride, MDD, Annual report, Gustav Neuring, Neurology, Form, CD40L, Obesity, Central nervous system, CNS, Sale, Prospectus, S-3, DSM-IV codes, Nature, Fibromyalgia, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering.

Key Points: 
  • CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering.
  • All of the securities to be sold in the offering are to be offered by Tonix.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the public offering, the timing and size of the public offering, the intended use of proceeds from the public offering and other statement that are predictive in nature.

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission

Retrieved on: 
Monday, September 18, 2023
Vaccine, Epidemic, BioNTech, Partnership, Vaccination, Public, Coalition, CEPI, Infection, Clinical trial, Malaria, Coalition for Epidemic Preparedness Innovations, Smallpox, History, Messenger, G7, MPXV, Monkeypox virus, Mpox, BNTX, G20, Knowledge, Pregnancy, Immunodeficiency, Virus, Safety, Tuberculosis, Orthopoxvirus

Since the eradication of smallpox in 1980, the global population-level immunity against the Orthopoxvirus viral family, including mpox, has been waning3.

Key Points: 
  • Since the eradication of smallpox in 1980, the global population-level immunity against the Orthopoxvirus viral family, including mpox, has been waning3.
  • BioNTech is aiming to develop a prophylactic mRNA-based mpox vaccine with a favorable safety profile that can be manufactured at scale.
  • The partnership between BioNTech and CEPI could help accelerate responses to future outbreaks caused by viruses of the Orthopoxvirus viral family in several ways.
  • BioNTech and CEPI are committed to enabling equitable access to the outputs of this partnership.

Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023

Retrieved on: 
Thursday, September 14, 2023
Long COVID, Psychiatry, Prader–Willi syndrome, Headache, Central nervous system, Sumatriptan, Obesity, Failure, Therapy, Binge eating disorder, COVID-19, Infection, Cancer, Smallpox, PPAR, SL, Disease, Research, Risk, Upsher-Smith Laboratories, CNS, Autoimmunity, Government, Pain, Breakthrough therapy, Hydrogen chloride, Orphan drug, MDD, DSM-IV codes, Annual report, Gustav Neuring, Neurology, Social anxiety disorder, Fibromyalgia, Security (finance), FDA, Migraine, CD40L, Long, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.

Key Points: 
  • Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.
  • Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates.
  • Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
  • Enrollment in a Phase 2 proof-of-concept study has been completed, and topline results were reported in the third quarter of 2023.

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 12, 2023
CLL, Vaccine, Chronic lymphocytic leukemia, SARS-CoV-2, Public, Biotechnology, COVID-19, Smallpox, Head, Breast, Infection, Prostate, Messenger, Monoclonal antibody, Hematological Cancer Research Investment and Education Act, Labs, Patient, Cancer, Immunodeficiency, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, NIH, Conference, Food, Pfizer, MVA, Pharmaceutical industry, Moderna

ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing  immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a company overview during the H.C. Wainwright 25th Annual Global Investment Conference on September 11. A webcast replay of Mr. Dodd’s presentation can be viewed here.

Key Points: 
  • ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing  immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a company overview during the H.C. Wainwright 25th Annual Global Investment Conference on September 11.
  • A webcast replay of Mr. Dodd’s presentation can be viewed here .
  • During his presentation, Mr. Dodd reviewed the Company’s four ongoing Phase 2 clinical trials:
    As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy).
  • As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine.

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

Retrieved on: 
Wednesday, September 6, 2023
Contact tracing, University, Internal medicine, Public, EVP, COVID-19, Smallpox, Infection, COVID, CMO, Harvard College, CDC, MPOX, SIGA Technologies, Interdisciplinary Association for Population Health Science, Risk, Chief Medical Officer (Australia), Weill Cornell Medicine, Safety, Management, Pharmaceutical industry, Vaccine

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO).

Key Points: 
  • NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO).
  • He will also continue to serve as a director of the SIGA Board of Directors.
  • “In his new additional role as EVP and Chief Medical Officer, he will be positioned to apply even more of his outstanding insight and experience to support our advocacy efforts.”
    As EVP and CMO, Dr. Varma will lead medical affairs.
  • SIGA plays a central role in helping countries around the world understand and respond to potential outbreaks of smallpox, MPOX and other orthopox viruses,” said Dr. Varma.

Simon Schama's history of 18th and 19th century disease outbreaks speaks powerfully to the present

Retrieved on: 
Sunday, September 3, 2023
Foreign Bodies, Plague, United States Senate Committee on Public Health and National Quarantine, Disease, BBC, Vaccination, Spanish flu, Politics, Public, Review, Health, Suez Canal, Smallpox, OECD, World War I, Head, Pandemic, Medicine, COVID, History, Quarantine, Aztecs, Ottoman Empire, Simon & Schuster, Vaccine, Population, Time, Cholera, Black Death, Knowledge, City, Black, Tourism, Nursing, Simon Schama, Christianity, Nation, Waldemar Haffkine, Jews

These concepts have been at the forefront of our minds for over three years now.

Key Points: 
  • These concepts have been at the forefront of our minds for over three years now.
  • Having lived through the height of the COVID pandemic, it would be easy for us to imagine we have just experienced something unique in human history.
  • In Foreign Bodies, Schama demonstrates that the histories of medicine and public health are deeply entwined with broader understandings of social history.
  • This is what Schama does best: he uses the macro history to highlight the intricacies of the micro histories.

The ‘other’

    • We have a natural tendency to look for an “other” to blame – people from other cultures that we do not truly understand.
    • This is exemplified by Waldemar Haffkine, the central figure in much of Schama’s narrative.
    • Of Jewish origin, Haffkine was the “other”: a person whose ancestors have often borne the blame for pandemics throughout European history.
    • In the 14th century, for example, at the time of the Black Plague, it was believed that Jewish people were poisoning wells.

Inoculation

    • During her time in Turkey, Lady Montagu was exposed to the traditional practice that would come to be known in European medical circles as inoculation (or variolation).
    • Inoculation was seen as counterproductive to many in the English medical establishment and viewed with suspicion in broader society.
    • Schama highlights that the form of inoculation Lady Montagu introduced to English society was not, in fact, an entirely new concept within the British Isles.
    • He touches on the fact that versions of inoculation were already practised in Wales and the Scotish Highlands.

Medicine and politics

    • Foreign Bodies is heavily invested in the history of the intersection of medicine and politics.
    • Schama examines the role of the great European powers of the 18th and 19th centuries in the management of pandemics and the proliferation of life-saving medical procedures, such as vaccination.
    • Of course, the rules of quarantine did apply to non-European travellers, as Schama demonstrates, indicating once again where the blame was being squarely placed.
    • There is an extensive list of disease outbreaks that Schama could have chosen to explore this concept.
    • If you want to believe scientific knowledge will eventually prevail, he observes, “it is probably best not to ask a historian”.

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox

Retrieved on: 
Monday, August 21, 2023
Vaccine, Infection, Medicine, Vaccination, COVID-19, New Drug Application, Smallpox, Mpox, Global health, History, Animal, Risk, Smallpox vaccine, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Phenotype, Food, Safety, Disease, Pharmaceutical industry, COVID, Tonix Pharmaceuticals, IND

CHATHAM, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) --  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it received the official written response from a Type B pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) to develop TNX-8011 (recombinant horsepox virus, live vaccine) as a potential vaccine to protect against mpox disease (formerly known as monkeypox) and smallpox. Tonix believes the FDA feedback provides a path to agreement on the design of a Phase 1/2 study and the overall clinical development plan. The Phase 1/2 clinical trial will assess the safety, tolerability, and immunogenicity of TNX-801, following the submission and clearance of an IND.

Key Points: 
  • Tonix believes the FDA feedback provides a path to agreement on the design of a Phase 1/2 study and the overall clinical development plan.
  • The Phase 1/2 clinical trial will assess the safety, tolerability, and immunogenicity of TNX-801, following the submission and clearance of an IND.
  • The “take” is a functional measure of protective T-cell immunity validated by the eradication of smallpox.
  • Live replicating vaccines have the potential to induce durable T-cell immunity, prevent serious illness after infection and block forward transmission.

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

Retrieved on: 
Thursday, August 17, 2023
Long COVID, Psychiatry, Prader–Willi syndrome, Headache, Central nervous system, Sumatriptan, Obesity, Failure, Therapy, IR, Binge eating disorder, COVID-19, Infection, Cancer, Smallpox, PPAR, SL, Disease, Research, Risk, Upsher-Smith Laboratories, CNS, Autoimmunity, Government, Pain, Breakthrough therapy, Hydrogen chloride, Orphan drug, MDD, DSM-IV codes, Annual report, Neurology, Social anxiety disorder, Fibromyalgia, Security (finance), FDA, Migraine, CD40L, Long, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m.

Key Points: 
  • CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator.
  • A webcast of the presentation can be found here and will be available under the IR Events tab of the Tonix website at www.tonixpharma.com .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

Retrieved on: 
Tuesday, August 8, 2023
BAT, Travel, ACAM2000, EBS, RSDL, Public, Ebola, Smallpox, Sale, Government, CDMO, OTC, Growth, FDA, Anthrax, BARDA, NYSE, Pharmaceutical industry, Vaccine, Emergent

GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services business. As a result, Emergent is reducing operations at its Bayview facility in Baltimore, Maryland.

Key Points: 
  • Going forward, Emergent will focus on its core products business – medical countermeasures and NARCAN® Nasal Spray –and on delivering for its existing customers, including the U.S. and allied governments.
  • Emergent will maintain a level of operations at both Bayview and Canton to ramp up production in response to new demand.
  • “The actions we are taking will further strengthen our core products business and financial foundation,” said Emergent interim Chief Executive Officer Haywood Miller.
  • As a result of the strategic shift away from Emergent’s services business, the company is eliminating the chief operating officer (COO) role.